Oncology, Patient, Child, Doctor, Cancer care, Treatment, MDX, Doctor making child laugh

Syndromic testing

Syndromic testing for GI infections with QIAstat-Dx

New: Transform gastrointestinal care with QIAstat-Dx

16 targets*. 1 sample. 1 step. ~1 hour. QIAstat-Dx Gastrointestinal Panel 2 delivers accurate, actionable results quickly and can help you transform your diagnostic process.

With just 200 μL preserved stool sample (Para-Pak C&S), detect and differentiate 16 bacterial, viral and parasitic targets* in about an hour. Our panel offers broad pathogen coverage with an emphasis on clinically actionable targets to help you improve treatment decisions. Get the flyer to learn more.

Download the flyer

The targets

* Results for STEC, E. coli O157 and EPEC are not reported for stool specimens preserved in FecalSwab transport media.

**Also Known as Giardia intestinalis and Giardia duodenalis.

Why is QIAstat-Dx Gastrointestinal Panel 2 right for your patients?

It doesn't get easier than this – QIAstat-Dx workflow***

***When using QIAstat-Dx Gastrointestinal Panel 2, you must select the correct sample type on the instrument touchscreen based on the sample collection device used (Para-Pak C&S or FecalSwab).

We're confident QIAstat-Dx can transform the way you diagnose GI symptoms

Make the right choice for your lab and get in touch today.

Caution around detecting stx2f-producing STEC, subtype of concern

Shiga-like toxin-producing E. coli (STEC) infections can result in severe disease outcomes (1). This includes hemolytic uremic syndrome (HUS), a serious condition that can lead to kidney failure.

Importantly, antibiotics are contraindicated for patients with STEC infection, as they can increase the risk of HUS (2)
The fast identification of stx1/stx2-producing STEC can help reduce the risk for serious complications, guide patient management and improve overall patient outcomes

Leading public health organizations, such as the ECDC and the UK Health Security Agency, have recently highlighted a notable increase in gastrointestinal illnesses linked to stx2f.

This stx subtype is now recognized as a significant emerging threat (3,4).

Due to its genetic divergence from other stx2 subtypes, standard PCR primers can fail to detect stx2f, leading to potential underreporting (3)
Unlike some other syndromic tests, QIAstat Dx Gastrointestinal Panel 2 effectively detects the stx2f subtype (5,6), ensuring comprehensive diagnostic coverage

Gastrointestinal co-detections are an important contributor to positive tests

Double, triple and even quadruple gastrointestinal co-detections are common, especially in children (7).

Our QIAsphere data corroborates this. We see a variety of co-detection types, including triple detections between a virus, bacteria and parasite (8).

Ct values can help you understand co-detections

When two or more pathogens are co-detected, doctors need to decide which pathogen to act on. This can impact the choice of treatment. Antibiotics that are appropriate for one co-detection (e.g., EPEC and Shigella) might be contraindicated for another (e.g., STEC stx2 and Salmonella).

In cases like these, additional insights from cycle threshold (Ct) values can aid in clinical interpretation.

Co-infection rates based on all positive detections between January – December 2023 (8).

QIAstat-Dx Gastrointestinal Panel 2 for immunocompromised lung transplant patients

According to Laurence Armand-Lefevre, PhD, PharmD, Professor of Microbiology at University of Paris Cité and Head of the Bacteriology Department at Bichat-Claude Bernard Hospital, France: "A few months after the implementation of the QIAstat-Dx [gastrointestinal panel], physicians in charge of the immunocompromised lung transplant patients asked us to perform multiplex PCR tests for all their patients, whatever their date of hospitalization. Lung transplant patients frequently have diarrhea and the physician needs to know is this diarrhea an adverse effect of the immunosuppressive treatment, which occurs frequently, or due to the acquisition of a GI pathogen. This test was of particular interest for them."

This clinical case was conducted using QIAstat-Dx Gastrointestinal Panel 2 (Cat. No. 691412). This CE-IVD product is not available in the U.S.

The importance of accurate detection

To provide timely care, you need accurate results. False negatives and false positives can be a major stumbling block. A missed positive can impact on infection control and delay time to appropriate treatment. False positives can also have serious consequences, masking the true cause of symptoms. This could lead to a delay in diagnosis, unnecessary implementation of infection control measures and increased hospital costs.

Norovirus false positives, for example, can have a negative impact on immunocompromised and oncology patients. These patients often experience diarrhea that goes undiagnosed. Accurate pathogen detection can improve their clinical management (9).

mature male patient, caretaker, wheeled chair

I think that [Ct values] can help in the interpretation of the results, in particular in case of co-infections, in order to understand what is the virus or the bacteria that is probably more correlated with the clinical problem.

Liliana Gabrielli, MD, Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria of Bologna, Policlinico di Sant'Orsola, Italy

It's clear. [The technicians in my lab] love the QIAstat-Dx. Because it's really easy to use… Because they feel that the search for pathogens is smarter.

Laurence Armand-Lefevre, PhD, PharmD, University of Paris Cité, Bichat-Claude Bernard Hospital, France

Disrupt the everyday with digital tech in medicine

More to explore

Contact us

References

1. Orth D, Grif K, Khan AB, Naim A, Dierich MP, Würzner R. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. Diagn Microbiol Infect Dis. 2007;59(3):235-242. doi:10.1016/j.diagmicrobio.2007.04.013
2. Mühlen S, Dersch P. Treatment Strategies for Infections With Shiga Toxin-Producing Escherichia coli. Front Cell Infect Microbiol. 2020 May 6;10:169. doi: 10.3389/fcimb.2020.00169. PMID: 32435624; PMCID: PMC7218068.
3. European Centre for Disease Prevention and Control Annual Epidemiological Report 2021 – STEC https://www.ecdc.europa.eu/sites/default/files/documents/AER%20STEC%20-%202021.pdf. Accessed February 7, 2024
4. Den Ouden A, Greig DR, Rodwell EV, et al. Escherichia coli encoding Shiga toxin subtype Stx2f causing human infections in England, 2015-2022. J Med Microbiol. 2023;72(6):10.1099/jmm.0.001707. doi:10.1099/jmm.0.001707
5. Engberg J, Vejrum LK, Madsen TV, Nielsen XC. Verification of analytical bacterial spectrum of QIAstat-Dx® GI V2 and Novodiag® Bacterial GE+ V2-0 diagnostic panels. J Antimicrob Chemother. 2021;76(Suppl 3):iii50-iii57. doi:10.1093/jac/dkab242
6. Cointe A, Birgy A, Pascault A, et al. Be aware of Shiga-toxin 2f-producing Escherichia coli: case report and false-negative results with certain rapid molecular panels. Diagn Microbiol Infect Dis. 2020;98(4):115177. doi:10.1016/j.diagmicrobio.2020.115177|
6. From QIAstat-Dx Gastrointestinal Panel 2 (Cat. No. 691412) epidemiology dashboards in QIAsphere Insights, January 2023 – December 2023 for EMEA.*****
8. Johansen RL, Schouw CH, Madsen TV, Nielsen XC, Engberg J. Epidemiology of gastrointestinal infections: lessons learned from syndromic testing, Region Zealand, Denmark. Eur J Clin Microbiol Infect Dis. 2023 Sep;42(9):1091-1101. doi: 10.1007/s10096-023-04642-5. Epub 2023 Jul 19. PMID: 37468662; PMCID: PMC10427544. Study performed using QIAstat-Dx Gastrointestinal Panel (V1).
9. Rogers WS, Westblade LF, Soave R, et al. Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2020;71(7):1693-1700. doi:10.1093/cid/ciz1068

*****These studies were conducted using QIAstat-Dx Gastrointestinal Panel 2 (Cat. No. 691412) or QIAstat-Dx Gastrointestinal Panel (V1). These CE-IVD products are not available in the U.S.

QIAsphere data from connected institutions were used for scientific research purposes only after applying proper de-identification procedures and anonymization techniques, in accordance with HIPAA and GDPR privacy and data protection rules. Data is aggregated from QIAsphere-connected QIAstat-Dx instruments only.

Unless otherwise indicated, data cited pertains to the use of a device from another manufacturer.